Caris Life Sciences, Inc. CAI
19.50 USD -0.44 (-2.21%)
Regular-session close
19.50 0.00 0.00%
After hours · Nov 18, 4:26 PM ET
19.28 Day range 20.44
14.19 52-week range 36.50
- YTD
- -27.72%
- 1 year
- -17.93%
News
businesswire.com CAI Enters Into a Definitive Agreement with PQE Group, Expanding Global Life Sciences Reach INDIANAPOLIS--(BUSINESS WIRE)--CAI, a professional services firm dedicated to accelerating operational readiness and excellence in life sciences and mission-critical environments, has entered into a…benzinga.com Piper Sandler Maintains Neutral on Caris Life Sciences, Raises Price Target to $25 Piper Sandler analyst David Westenberg maintains Caris Life Sciences (NASDAQ:CAI) with a Neutral and raises the price target from $22 to $25.
zacks.com BTSG vs. CAI: Which Stock Should Value Investors Buy Now? Investors looking for stocks in the Medical Services sector might want to consider either BrightSpring Health Services, Inc. (BTSG) or Caris Life Sciences,?Inc. (CAI). But which of these two…benzinga.com Citigroup Maintains Buy on Caris Life Sciences, Raises Price Target to $36 Citigroup analyst Albert Hu maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and raises the price target from $28 to $36.
benzinga.com TD Cowen Maintains Buy on Caris Life Sciences, Raises Price Target to $38 TD Cowen analyst Dan Brennan maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and raises the price target from $36 to $38.
benzinga.com VIX Spikes 39% as AI Tech Rout Wipes Out $2.2 Trillion: Stock Market Today The AI sell-off deepens after the Democratic midterm sweep, sending the S&P 500 toward its worst day since April 2025 as Nvidia, AMD and Micron sank.
benzinga.com Zillow Posts Downbeat Q3 Results, Joins HubSpot, Snap And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session U.S. stock futures were mixed as Zillow and several companies fell sharply premarket after weak results and lowered sales guidance.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers ADMA Biologics (NASDAQ:ADMA) shares rose 19.6% to $12.53 during Thursday's pre-market session. The market value of their outstanding shares is at $2.3 billion. As per the news, the Q3…
seekingalpha.com Caris Life Sciences, Inc. (CAI) Q3 2026 Earnings Call Transcript Caris Life Sciences, Inc. (CAI) Q3 2026 Earnings Call Transcript
marketbeat.com Caris Life Sciences Q3 Earnings Call Highlights Caris Life Sciences NASDAQ: CAI raised its full-year revenue outlook after third-quarter sales rose 27%, as growth in cancer-testing volumes accelerated for a second consecutive quarter. The company…
zacks.com Caris Life Sciences,?Inc. (CAI) Q3 Earnings and Revenues Top Estimates Caris Life Sciences,?Inc. (CAI) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.08 per share a year ago.
benzinga.com Caris Life Sciences Q3 2026 Earnings Call Transcript Caris Life Sciences (NASDAQ:CAI) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide…benzinga.com Caris Life Sciences Raises FY2026 Sales Guidance from $1.030B-$1.040B to $1.040B-$1.050B vs $1.030B Est Caris Life Sciences (NASDAQ:CAI) raises FY2026 sales outlook from $1.030 billion-$1.040 billion to $1.040 billion-$1.050 billion vs $1.030 billion estimate.
benzinga.com Caris Life Sciences Q3 EPS $0.05 Beats $0.04 Estimate, Sales $275.358M Beat $255.363M Estimate Caris Life Sciences (NASDAQ:CAI) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.04 by 25 percent. This is a 37.5 percent decrease over earnings of…
prnewswire.com Caris Life Sciences Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance Revenue growth of 27% driven by strong performance in molecular profiling services, including approximately 61,500 clinical cases, consisting of over 358,000 total oncology tests Raises 2026 revenue…
zacks.com Analysts Estimate Caris Life Sciences,?Inc. (CAI) to Report a Decline in Earnings: What to Look Out for Caris Life Sciences,?Inc. (CAI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.benzinga.com BTIG Maintains Buy on Caris Life Sciences, Raises Price Target to $38 BTIG analyst Mark Massaro maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and raises the price target from $33 to $38.
benzinga.com Canaccord Genuity Maintains Hold on Caris Life Sciences, Raises Price Target to $30 Canaccord Genuity analyst Kyle Mikson maintains Caris Life Sciences (NASDAQ:CAI) with a Hold and raises the price target from $22 to $30.
prnewswire.com Caris Life Sciences Launches New National Commercial Featuring Jordan Spieth Highlighting the Power of Artificial Intelligence in Early Stage Cancer Detection New campaign connects AI-powered performance insights linking advanced molecular intelligence to help detect cancer in earlier stages IRVING, Texas, Oct. 19, 2026 /PRNewswire/ -- Caris Life Sciences®…
prnewswire.com Caris Life Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026 IRVING, Texas, Oct. 15, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading TechBio company, today announced it will report third quarter 2026 financial results on Wednesday, November…
prnewswire.com Caris Life Sciences to Present Eight Studies Highlighting the Power of AI, Multi-Omics and Precision Medicine at ESMO 2026 Eight posters will feature AI-driven approaches to treatment prediction, risk stratification and biomarker discovery advancing precision medicine across multiple cancer types IRVING, Texas, Oct. 14,…
defenseworld.net Caris Life Sciences, Inc. $CAI Shares Newly Bought by City Center Advisors LLC City Center Advisors LLC acquired a new stake in Caris Life Sciences, Inc. (NASDAQ: CAI) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission.…
investors.com IPO Stock Of The Week: Caris Pulls Back After More Than Doubling In Just Two Months Caris stock is pulling back after more than doubling in just two months. Wait for the IPO stock to offer a new buy point.
seekingalpha.com Caris Life Sciences: Diagnostics Growth With Room To Run Caris Life Sciences has an already established profiling business that provides revenue and cash flows for its expanding diagnostics portfolio. CAI reuses molecular data and clinical relationships,…
zacks.com Caris Life Sciences, Inc. (CAI) Soars 9.4%: Is Further Upside Left in the Stock? Caris Life Sciences, Inc. (CAI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in…
prnewswire.com Caris Life Sciences Launches New National Commercial Featuring Kevin Costner to Raise Awareness of Early Cancer Detection and Caris Detect New partnership highlights the importance of finding cancer earlier through Caris Detect, a multi-cancer early detection blood test now available nationwide IRVING, Texas, Sept. 8, 2026 /PRNewswire/…
prnewswire.com Caris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancer Seven studies will be presented, including two mini oral presentations and a poster tour presentation IRVING, Texas, Sept. 2, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading…
proactiveinvestors.co.uk Caris Life Sciences study finds AI tool could guide pancreatic cancer treatment choice Caris Life Sciences (Nasdaq:CAI), the Nasdaq-listed Techbio company, has published a study describing an artificial intelligence (AI) tool designed to help doctors choose first-line treatment for…
prnewswire.com Caris Life Sciences Publishes npj Precision Oncology Study Showing AI-Guided Therapy Selection is Predictive of Longer Survival in Patients with Pancreatic Cancer Caris AI Insights for pancreatic cancer is proprietary, only available to Caris Life Sciences customers and not achievable through small panels IRVING, Texas, Aug. 27, 2026 /PRNewswire/ -- Caris Life…
seekingalpha.com Caris Life Sciences: Guidance Raised, Valuation Still Attractive Caris Life Sciences delivered another strong quarter, raising full-year guidance and expanding margins while sustaining positive free cash flow. Accelerating clinical volume growth and the commercial…
seekingalpha.com Caris Life Sciences, Inc. (CAI) Q2 2026 Earnings Call Transcript Caris Life Sciences, Inc. (CAI) Q2 2026 Earnings Call Transcript
